Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis

Pharmacological Research : the Official Journal of the Italian Pharmacological Society
Rosita SaracenoSergio Chimenti

Abstract

Psoriasis is a lifelong, chronic and immune-mediated skin disease affecting approximately 1-3% of the Caucasian population. Pathogenesis of psoriasis is associated with an increased expression of tumor necrosis factor-alpha (TNF-alpha). TNF-alpha is a pro-inflammatory cytokine and important mediator of cachexia. Anti-TNF-alpha therapies are effective in the treatment of psoriasis. The primary end-point was to investigate retrospectively the effect of anti-TNF-therapies on body weight and body mass index (BMI) in patients with psoriasis under treatment with infliximab, etanercept, adalimumab (anti-TNF-alpha group), efalizumab or methotrexate (control group). The patients were treated for 48 weeks. BMI, weight and disease activity were measured at baseline (week 0), weeks 12, 24 and 48. At week 24 a significant increase in body weight and BMI in the anti-TNF-alpha treatment group compared to the control was observed. BMI and body weight did not interfere with the drugs' efficacy. We report a significant weight-gain associated with three different anti-TNF-alpha therapies in a large number of patients affected with psoriasis.

Citations

Sep 6, 2013·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Marina PapoutsakiAntonio Costanzo
Jun 30, 2009·Actas dermo-sifiliográficas·L PuigUNKNOWN Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología
Feb 9, 2011·Arthritis Research & Therapy·Paulo G PedreiraVera L Szejnfeld
May 16, 2012·Arthritis Research & Therapy·Sébastien OttavianiPhilippe Dieudé
Jan 1, 2009·Clinical, Cosmetic and Investigational Dermatology·Thao U Nguyen, John Koo
Jan 1, 2009·Clinical, Cosmetic and Investigational Dermatology·Jennifer D BahnerNeil J Korman
Jan 1, 2009·F1000 Medicine Reports·John Yost, Johann E Gudjonsson
Jul 1, 2010·Current Rheumatology Reports·M Elaine Husni, Philip J Mease
Oct 15, 2013·Canadian Journal of Physiology and Pharmacology·Nathalie QuinsonAnne Abysique
Jun 22, 2010·Expert Opinion on Biological Therapy·Gérald E PiérardPascale Quatresooz
Jan 19, 2010·Expert Opinion on Biological Therapy·Ala IaconiRajesh Balkrishnan
Nov 28, 2012·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Qing-Tong WangWei Wei
Oct 30, 2010·Medical Hypotheses·Kamran MansouriMaryam Keshavarz
Jun 16, 2010·The British Journal of Dermatology·G BandoliC D Chambers
Jun 15, 2015·Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban·Feng HuHong-Xiang Chen
Dec 21, 2014·Reviews in Endocrine & Metabolic Disorders·Hui Wang, Jianping Ye
Jul 6, 2016·Journal of Biomedical Science·Ilaria PelusoMaura Palmery
Aug 25, 2016·Reviews in Endocrine & Metabolic Disorders·Kerstin Wolk, Robert Sabat
Sep 10, 2016·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Xiang ChenXi-Jie Yu
Jan 19, 2017·Anais Brasileiros De Dermatologia·André Vicente Esteves de CarvalhoLuana Pizarro Meneghello
Jun 18, 2017·Journal of the European Academy of Dermatology and Venereology : JEADV·N H ShearA W Armstrong
Oct 27, 2017·International Journal of Molecular Sciences·Stephen Chu-Sung Hu, Cheng-Che E Lan
Sep 30, 2016·The Journal of International Medical Research·Alessandro GiuntaMaria Esposito
Apr 27, 2010·Dermatologic Therapy·Gino A VenaNicoletta Cassano
Feb 2, 2019·Journal of the European Academy of Dermatology and Venereology : JEADV·D Wcisło-DziadeckaC Kruszniewska-Rajs
May 25, 2012·Journal of the European Academy of Dermatology and Venereology : JEADV·V FlorinD Staumont-Sallé
Jan 3, 2013·Journal of the European Academy of Dermatology and Venereology : JEADV·E MahéUNKNOWN GEM Resopso
Apr 9, 2014·Journal of the European Academy of Dermatology and Venereology : JEADV·J J WuL J Herrinton
Apr 8, 2015·World Journal of Hepatology·Giulia GanzettiAnnamaria Offidani
Sep 6, 2019·The British Journal of Dermatology·A MuntyanuP Fleming

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Cardiac Cachexia

Cardiac cachexia is a syndrome associated with the progressive loss of muscle and fat mass. It most commonly affects patients with heart failure and can significantly decrease the quality of life and survival in these patients. Here is the latest research on cardiac cachexia.

Cachexia & Brown Fat

Cachexia is a condition associated with progressive weight loss due to severe illness. In cancer patients, it is proposed to occur as a result of tumor-induced energy wasting. Several proteins have been implicated in browning and depletion of white adipose tissue. Here is the latest research on cachexia and brown fat.